Skip to main content
OpenTrials
Completed

NCT Number: NCT02903225

Clinical Value of Heart Rate Variability Indexes to Predict Outcomes After Exercise Training in Chronic Heart Failure

Controlled exercise training is a valuable therapeutic addition to pharmacological treatment in most patients with chronic heart failure, reducing long-term mortality, preventing cardiac remodeling and improving functional capacity. Despite the mechanism underlying its benefits might be multifactorial, a sustained improvement in autonomic balance is usually attributed as a major effect. Nevertheless, not all eligible subjects show the same response to exercise, probably due to several differences in the subpopulations enrolled. The investigators hypothesize that some Heart Rate Variability indexes could be valid tools to optimize the selection and follow-up of chronic heart failure patients to training

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

About this study

Forty subjects followed in a University Heart Failure Management Program were prospectively included. All patients were evaluated before the randomization and after 24 weeks from enrollment. The investigators performed a detailed anamnesis and complete physical examination, Doppler echocardiography, Stress Testing, 6-minute walk test, heart rate variability analysis, and quality of life test. Patients were randomized either to a training group: performing a supervised training program, or a control group receiving usual care. All patients received an optimal pharmacologic treatment including diuretics, angiotensin converting enzyme inhibitors or angiotensin receptor blockers and beta-adrenergic blocking agents. All patients included in the training group attended a supervised program 3-days/week during 24 weeks (68-74 sessions). Physical aerobic training appears to impart beneficial changes in autonomic control of patients with chronic heart failure through both parasympathetic and sympathetic control of hear rate. These effects produce changes in several Heart Rate Variability indices as HF and rMSSD related with parasympathetic tone.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • subjects followed in a University Heart Failure Management Program
  • maintained sinus rhythm
  • New York Heart Association Functional Class (NYHA) I to III and
  • LVEF≤40% documented by echocardiogram
  • optimal pharmacologic treatment

Exclusion criteria

  • history of stroke, myocardial infarction or extended anterior myocardial scar
  • revascularization procedures or recurrent angina within previous 3 months
  • orthopedic impairment
  • alcohol or drug abuse;
  • implant of pacemaker or cardioverter-defibrillator (AICD);
  • frequently ventricular dysrhythmias,
  • atrial flutter or fibrillation
  • insulin-dependent diabetes mellitus;
  • severe chronic obstructive pulmonary disease or renal dysfunction
  • comorbid non-cardiac disease limiting short term survival
  • previous enrollment in an ET program
  • subjects at great propensity for noncompliance

Treatment and study plan

Cardiac rehabilitation

Behavioral

All patients included in this group attended a supervised exercise training program. A cardiologist supervised the hole training sessions. Blood pressure, pulse rate, oxygen saturation, and body weight were measured in each session. The modified Borg scale was used to measure the perceived exercise intensity

Other names: Exercise training, Educational approach

Primary outcomes

  1. Clinical Events

    Time frame: 6 month

    Change in New York Heart Association Functional Class; Number of hospitalizations 6 months before and after the date of enrollment; temporary or permanent withdrawal from the study protocol (due to persistent atrial or ventricular arrhythmias; worsening of congestive heart failure symptoms; myocardial infarction; unstable angina; need of cardiac interventions: pacemaker, implantable cardioverter defibrillator, coronary revascularization or cardiac transplantation; stroke or transient ischemic attack; severe peripheral intermittent claudication or death observed during training or follow-up sessions

  2. Mean heart rate

    Time frame: 6 month

    the mean value of the12-min Electrocardiogram-recordings was considered the resting heart rate (beats per minute)

  3. 6 minute walk test

    Time frame: 6 month

    walking along a 20-meter long corridor at their own pace, with the aim of covering as much ground as possible in 6 minutes. The distance walked was expressed in meter

  4. left ventricular ejection fraction

    Time frame: one year

    The area-length method was measured to obtain biplane left ventricle volumes. Left Ventricle ejection fraction was derived from the standard equation (%)

  5. quality of life

    Time frame: 6 month

    All the subjects completed the Short-Form 36 Health Survey (SF-36), available in its Spanish version, for measuring physical and mental quality of life

  6. Stress Test

    Time frame: 6 month

    symptom limited exercise testing, measured in metabolic unit (MET)

  7. square root of the mean squared successive differences of R-R intervals (rMSSD)

    Time frame: 6 month

    short-term continuous electrocardiographic recordings were performed for heart rate variability analysis. In the time domain, the square root of the mean squared successive differences of R-R intervals (rMSSD) were calculated. Units: ms

  8. Heart rate power high-frequency (HF)

    Time frame: 6 month

    The high-frequency (HF), from 0.15 to 0.40 Hz of the power spectral analysis were calculated. Units: ms2/Hz

Sponsors and collaborators

Lead sponsor

Universidad de la Republica

Other

Registry information

Acronym: REINCA

Important dates

Study start
2010
Primary completion
2013
Study completion
2014
First posted
Sep 16, 2016
Registry last updated
Sep 16, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.